Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIRAD: Everolimus in Adjuvant Hormone Therapy for High Risk ER+/HER2- Breast Cancer
NCT01805271Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Mar 2013
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in breast cancer, sponsored by Unicancer. Started Mar 2013; status: active, not recruiting.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01805271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805271.